Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Cash & Equivalents: 2021-2024

Historic Cash & Equivalents for ProQR Therapeutics N.V (PRQR) over the last 4 years, with Dec 2024 value amounting to $159,657.

  • ProQR Therapeutics N.V's Cash & Equivalents rose 127165.90% to $125.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.0 million, marking a year-over-year increase of 127165.90%. This contributed to the annual value of $159,657 for FY2024, which is 24.11% up from last year.
  • ProQR Therapeutics N.V's Cash & Equivalents amounted to $159,657 in FY2024, which was up 24.11% from $128,643 recorded in FY2023.
  • ProQR Therapeutics N.V's Cash & Equivalents' 5-year high stood at $221.9 million during FY2021, with a 5-year trough of $128,643 in FY2023.
  • In the last 3 years, ProQR Therapeutics N.V's Cash & Equivalents had a median value of $159,657 in 2024 and averaged $32.3 million.
  • In the last 5 years, ProQR Therapeutics N.V's Cash & Equivalents slumped by 99.87% in 2023 and then increased by 24.11% in 2024.
  • ProQR Therapeutics N.V's Cash & Equivalents (Yearly) stood at $221.9 million in 2021, then tumbled by 56.43% to $96.7 million in 2022, then crashed by 99.87% to $128,643 in 2023, then rose by 24.11% to $159,657 in 2024.